Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
07/2003
07/24/2003US20030138931 Hydrolase polypeptide for dephosphorylating mitogen activated kinases (MAP-kinase); antiapoptosis; antiproliferative agents
07/24/2003US20030138910 Incubating blood for in vitro (syringe) induction of modulators to cytokine binding membrane protein; antiarthritic agents
07/24/2003US20030138884 APRIL- a novel protein with growth effects
07/24/2003US20030138864 Comparing expression levels of genes or proteins in human tissue or cells from normal and tumor origin, selecting enzyme of which mRNA or protein levels in tumor tissue are higher by two-fold as compared to normal cells or tissue
07/24/2003US20030138818 G-protein coupled receptors
07/24/2003US20030138798 Detecting genetic mutation in fibrillin like (FBNL) genes and modulators associated with loss of central vision; vision correction treatments
07/24/2003US20030138793 Kit for identifying the origin of tumors in prostate, breast, colorectal, lung, ovarian, gastroesophageal, pancreatic, liver, kidney or bladder cells by way of probes for analyzing marker gene expression
07/24/2003US20030138511 Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same
07/24/2003US20030138507 Plant extracts with anti-radical type action
07/24/2003US20030138423 Antiinflammation agents and immunotherapy using an enzyme inhibitor; sepsis; antiarthritic and - ulcer agents; colitis; myocarditis; glomerulonephritis; gastrointestinal and nervous system disorders; Crohn's disease; automimmune
07/24/2003US20030138414 Modulators of methylation for control of bacterial virulence
07/24/2003US20030138390 Aging resistance
07/24/2003CA2700690A1 Process for producing reformatsky reagent in stable form
07/24/2003CA2474239A1 Substituted pyridazinones as inhibitors of p38
07/24/2003CA2474141A1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
07/24/2003CA2474127A1 4-oxo-4, 7-dihydrofuro¬2,3-b|pyridine-5-carboxamide antiviral agents
07/24/2003CA2473908A1 Compounds for blocking androgen receptors
07/24/2003CA2473441A1 Beta-secretase inhibitors
07/24/2003CA2473236A1 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
07/24/2003CA2473229A1 Selective melanin-concentrating hormone type -1 receptor agonists
07/24/2003CA2473170A1 Therapeutic acridone and acridine compounds
07/24/2003CA2472993A1 Oxothieno (3, 2-b) pyridinecarboxamides as antiviral agents
07/24/2003CA2472746A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
07/24/2003CA2472619A1 Fused pyrimidine derivates as rho-kinase inhibitors
07/24/2003CA2472472A1 Treatment of bone disorders with skeletal anabolic drugs
07/24/2003CA2472470A1 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
07/24/2003CA2472419A1 Coumarin derivatives, process for their production and use thereof
07/24/2003CA2472223A1 Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation
07/24/2003CA2472168A1 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
07/24/2003CA2472160A1 Quinazolinone compounds in combined modalities for improved cancer treatment
07/24/2003CA2471907A1 Antibody-avidin fusion proteins as cytotoxic drugs
07/24/2003CA2471744A1 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation
07/24/2003CA2471620A1 Pyrrolidone carboxamides
07/24/2003CA2471562A1 Tyrosyl derivatives and their use as p2x7 receptor modulators
07/24/2003CA2471513A1 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease
07/24/2003CA2471311A1 Aromatic thioether liver x-receptor modulators
07/24/2003CA2471309A1 Synthesis of combretastatin a-2 prodrugs
07/24/2003CA2471192A1 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
07/24/2003CA2470970A1 Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs
07/24/2003CA2470649A1 Mmp inhibitors
07/24/2003CA2470413A1 Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients
07/24/2003CA2469800A1 Methods for the induction of professional and cytokine-producing regulatory cells
07/24/2003CA2469435A1 Modulators of lxr
07/24/2003CA2468610A1 Method for reducing morbidity and mortality in critically ill patients
07/24/2003CA2464805A1 D-tagatose as an anti-biofilm agent
07/23/2003EP1329501A1 Novel pla1
07/23/2003EP1329456A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
07/23/2003EP1329454A1 Thienopyrimidine compounds and their salts and process for preparation of both
07/23/2003EP1329451A1 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
07/23/2003EP1329223A1 Expression potentiator for protein synthesis regulatory gene
07/23/2003EP1329219A1 Apoptosis inducers, caspase cascade activators and anticancer agents
07/23/2003EP1329218A1 Preventives/remedies for portal hypertension
07/23/2003EP1328816A2 Regulation of neutral development by daedalos
07/23/2003EP1328653A2 Highly expressible genes
07/23/2003EP1328646A2 Regulation of human adenylate cyclase, type iv
07/23/2003EP1328635A2 Compositions and methods relating to lung specific genes
07/23/2003EP1328629A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
07/23/2003EP1328624A2 B7-like molecules and uses thereof
07/23/2003EP1328622A2 Protein c or activated protein c-like molecules
07/23/2003EP1328550A2 Methods of selecting compounds for modulation of bladder function
07/23/2003EP1328548A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
07/23/2003EP1328539A1 Vegf peptides and their use for inhibiting angiogenesis
07/23/2003EP1328527A1 Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents
07/23/2003EP1328525A2 2,3,4,5-tetrahydro-1h-[1,4]diazepino[1,7-a]indole compounds
07/23/2003EP1328521A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
07/23/2003EP1328519A2 Orally active salts with tyrosine kinase activity
07/23/2003EP1328516A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
07/23/2003EP1328515A1 Indoline derivatives and their use as 5-ht2 receptor ligands
07/23/2003EP1328514A1 Amide derivatives as nmda receptor antagonists
07/23/2003EP1328510A2 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
07/23/2003EP1328298A1 Methods and compositions for modulating t cell activation and uses thereof
07/23/2003EP1328292A2 Immunogenic compositions comprising liver stage malarial antigens
07/23/2003EP1328291A2 Viruses targeted to hypoxic cells and tissues
07/23/2003EP1328289A2 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
07/23/2003EP1328288A2 Protein mixtures for wound healing
07/23/2003EP1328284A1 Novel medicinal herbal composition for treating liver diseases and hiv
07/23/2003EP1328272A1 Nf-kappa-b inhibitors
07/23/2003EP1328271A2 Method for the treatment of neurological and neuropsychological disorders
07/23/2003EP1328270A2 Method for the treatment of neurological and neuropsychological disorders
07/23/2003EP1328269A2 Association of the cb1 receptor antagonist and a sibutramin for treating obesity
07/23/2003EP1328268A1 Combination of catechin and quercetin for pharmaceutical or dietary use
07/23/2003EP1328267A2 Method of treating cancer using dithiocarbamate derivatives
07/23/2003EP1328266A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction
07/23/2003EP1328265A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions
07/23/2003EP1328264A1 Use of estramustine phosphate in the treatment of bone metastasis
07/23/2003EP1328261A2 Treatment of neurodegenerative disease
07/23/2003EP1328253A2 Administration of a thiol-based chemoprotectant compound
07/23/2003EP1328245A1 Dental care compositions
07/23/2003EP1254134B1 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors
07/23/2003EP1228073B1 Imidazole compounds used as phosphodiesterase vii inhibitors
07/23/2003EP1204654B1 Benzofurylpiperazines: 5-ht2c serotonin receptor agonists
07/23/2003EP1163246B1 Organic-arsenic compounds
07/23/2003EP1154785B1 Inhibitors for use in hemostasis and immune function
07/23/2003EP1148876A4 Calcilytic compounds
07/23/2003EP1129093B1 Pyrazolopyrimidinone derivatives for the treatment of impotence
07/23/2003EP1089753B1 Use of a dipeptide for stimulating repair processes
07/23/2003EP1086096B1 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
07/23/2003EP1075259B1 Novel fatty analogues for the treatment of diabetes
07/23/2003EP1035842A4 IMPROVED HMG CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATION
07/23/2003EP1011716B1 Neuromedin b receptor antagonists
1 ... 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 ... 1564